Engineering Living Tissues Clinical Translation: From Dialysis Access Conduit to Congenital Heart Valves

Abstract

We present the strategic translational pathway for tissue engineered platform technology from bench to bedside, using Vascudyne's development program as an illustrative case study. We detail a deliberate approach where initial clinical introduction targeted adult end-stage renal disease patients requiring hemodialysis access—a population with significant unmet need and compelling risk-benefit profile. This strategic entry point allowed for valuable safety and performance data collection in a controlled clinical setting before expanding to higher-risk applications including coronary artery bypass grafting and, ultimately, pediatric congenital vascular defect repair and heart valve.

The talk will highlight how parallel regulatory engagement with FDA was structured during preclinical development for tissue engineered heart valve, while early clinical experience in adults provided critical supportive evidence for subsequent applications. Of particular significance, we will discuss the unique advantages of this translational approach, which yielded unprecedented insights into human immunological responses and tissue remodeling/regeneration patterns in clinically relevant disease states—data that proved far more valuable than traditional preclinical models using young, healthy animals. 

This experience offers important lessons for the field regarding optimizing the risk-benefit calculus during tissue engineering translation and suggests new paradigms for evidence generation in regenerative medicine product development, particularly for addressing challenging congenital valve defects.